双触发与促性腺激素释放激素激动剂单触发在择期生育力保存中的随机对照试验
这项单中心随机对照优效性 trial 纳入109例≤40岁、窦卵泡计数<20且抗苗勒管激素≤3 ng/mL的择期生育力保存女性,比较双触发(曲普瑞林0.2 mg+重组人绒毛膜促性腺激素250 mcg)与促性腺激素释放激素激动剂单触发(曲普瑞林0.2 mg)的获卵效果。结果显示两组获卵总数及MII卵母细胞数均无统计学显著差异,双触发未显示优效性,两组均未发生卵巢过度刺激综合征。
要点
- 双触发组与GnRH-a单触发组获卵总数分别为9.22±5.11与9.56±5.16,估计均值差-0.34(95%CI -2.29至1.61)。
- 双触发组与GnRH-a单触发组MII卵母细胞数分别为7.31±4.63与7.94±4.39,估计均值差-0.64(95%CI -2.07至0.80)。
- 两组均未出现卵巢过度刺激综合征病例。
核心结论
- 在生育力保存患者中,GnRH-a触发时加用人绒毛膜促性腺激素在MII卵母细胞数方面并不优于单用GnRH-a触发。
- 因此触发方式的选择应基于患者和临床医生的偏好,并关注患者的安全性和便利性。
研究设计与样本
- 随机、对照、单中心、优效性临床试验,2021年10月至2023年4月共纳入109例女性,按1:1分组。
- 纳入标准为年龄≤40岁、窦卵泡计数<20、抗苗勒管激素≤3 ng/mL且接受择期生育力保存周期。
- 控制性卵巢刺激使用225-300 IU/d的促卵泡激素α或β,或15-20 μg的促卵泡激素δ,根据卵巢储备和体重调整。
- 采用孕激素预处理卵巢刺激方案抑制黄体生成素峰,自卵巢刺激开始至触发日口服微粒化黄体酮200 mg/d。
- 超声见至少3个直径≥18 mm卵泡时随机分组:干预组为曲普瑞林0.2 mg+重组人绒毛膜促性腺激素250 mcg,对照组为单用促性腺激素释放激素激动剂曲普瑞林0.2 mg。
主要发现
- 共分析109例,双触发组55例,GnRH-a对照组54例。
- 双触发组与GnRH-a组的获卵总数分别为9.22±5.11与9.56±5.16,估计均值差-0.34(95%CI -2.29至1.61)。
- 双触发组与GnRH-a组的MII卵母细胞数分别为7.31±4.63与7.94±4.39,估计均值差-0.64(95%CI -2.07至0.80)。
- 两组触发次日雌二醇、孕酮、黄体生成素和促卵泡激素水平均无统计学显著差异。
- 两组均未出现卵巢过度刺激综合征病例。
关键数值与推荐
- 主要终点为双触发与GnRH-a触发后获取的MII卵母细胞数,两组差异无统计学显著(估计均值差-0.64,95%CI -2.07至0.80)。
- 获卵总数两组差异无统计学显著(估计均值差-0.34,95%CI -2.29至1.61)。
临床怎么用
- 作者认为在生育力保存患者中,GnRH-a触发时加用人绒毛膜促性腺激素在MII卵母细胞数方面不优于单用GnRH-a触发。
- 作者认为触发方式的选择应基于患者和临床医生的偏好,并关注患者的安全性和便利性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study aimed to compare the efficacy, in terms of mature oocytes, of dual trigger vs. agonist alone in good-prognosis patients undergoing elective fertility preservation. DESIGN: Randomized, controlled, single-center, superiority clinical trial. SUBJECTS: A total of 109 women were enrolled in this study between October 2021 and April 2023 with a 1:1 allocation. Eligible patients were ≤40 years old, with an antral follicular count of <20 and antimüllerian hormone level of ≤3 ng/mL undergoing elective fertility preservation cycles. INTERVENTION: Controlled ovarian stimulation was performed using 225-300 IU/d of follitropin α or β or 15-20 μg of follitropin δ, tailored to ovarian reserve and weight. Luteinizing hormone surge was suppressed through a progestin-primed ovarian stimulation protocol, with oral administration of micronized progesterone (200 mg daily) from the beginning of ovarian stimulation until the trigger day. As soon as at least three follicles measuring ≥18 mm were observed by ultrasound, patients were randomization to the intervention group (triptorelin 0.2 mg + recombinant human chorionic gonadotropin 250 mcg) or the control group trigger with gonadotropin-releasing hormone agonist (GnRH-a) alone (triptorelin 0.2 mg). MAIN OUTCOME MEASURES: The primary endpoint was the number of metaphase II (MII) oocytes retrieved after final oocyte maturation with dual trigger and GnRH-a trigger in patients undergoing elective fertility preservation. RESULTS: Overall, 109 patients were analyzed, 55 in the dual trigger group and 54 in the control arm (GnRH-a). No statistically significant differences were found regarding the total number of oocytes nor MII oocytes retrieved between the dual trigger and GnRH-a groups (9.22 ± 5.11 vs. 9.56 ± 5.16 [estimated mean difference, -0.34 {95% confidence interval, -2.29 to 1.61}] and 7.31 ± 4.63 vs. 7.94 ± 4.39 group [estimated mean difference, -0.64 {95% confidence interval, -2.07 to 0.80}], respectively). Likewise, no statistically significant differences were found regarding estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone levels on the day after the trigger. Notably, neither group exhibited any case of ovarian hyperstimulation syndrome. CONCLUSION: In patients undergoing fertility preservation, adding human chorionic gonadotropin to GnRH-a for triggering final oocyte maturation is not superior to the administration of GnRH-a alone in terms of MII oocytes. Therefore, the selection of the trigger method should be based on both patients' and clinicians' preferences, with a focus on patients' safety and convenience.
引用
- Donno V, Neves AR, García-Martinez S, et al. Dual trigger vs. gonadotropin-releasing hormone agonist trigger for elective fertility preservation: a randomized controlled trial. Fertil Steril. 2025. PMID: 40967454. doi:10.1016/j.fertnstert.2025.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。